Nachweis von TEL- Genrekombinationen mittels Southern Blot bei Kindern mit akuter lymphoblastischer Leukämie.Blanka Kothe 161.11.1.171.1.1.189101.1.1.2111.21.2.112622#1251.31.3.11.3.1.113624#1521.3.1.214151.3.1.3473#191161.3.21.3.2.1456#851.3.2.217613#1901.3.2.3486#1791.3.3191.3.3.1201.3.3.2537#2791.3.3.3211.4222233243.13.23.2.1253.2.23.2.2.13.2.2.226359#2423.2.2.33.2.2.43.2.33.2.4273.2.4.13.2.4.2283.2.4.3293.2.53.2.63.2.7303.2.7.13.2.83.2.9313.2.103.2.10.132623#6233.2.10.233604#2743.2.11343.2.11.13.3353.43.4.1363.4.23.4.33.4.43.4.5373.4.63.4.73.4.83.4.93.4.9.1383.4.9.23.4.9.33.4.103.4.11393.4.124404.14.1.14.1.1.14.1.1.2414.1.242564#223623#1624.1.34.1.4623#1624.2454.34.3.1464748494.450558#3985515.15.1.15.1.25.1.3525.25.2.15354555.2.256575.2.358659LiteraturverzeichnisErklärung an Eides StattdeInhaltsverzeichnisHilfe Literaturverzeichnis [1] Greaves, M. F. und Alexander, F. E. (1993): An infectious etiology for common acute lymphoblastic leukemia in childhood?, Leukemia, (Band 7), No. 3, Seite 349-60. [2] Margolin, J.F. und Poplack, D.G. (1997): Acute lymphoblastic leukemia, Principles and Practice of Pediatric Oncology. [3] Ross, J. A.; Davies, S. M.; Potter, J. D. und Robison, L. L. (1994): Epidemiology of childhood leukemia, with a focus on infants, Epidemiol Rev, (Band 16), No. 2, Seite 243-72. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0007713179 [4] Shu, X. O.; Ross, J. A.; Pendergrass, T. W.; Reaman, G. H.; Lampkin, B. und Robison, L. L. (1996): Parental alcohol consumption, cigarette smoking, and risk of infant leukemia: a Childrens Cancer Group study, J Natl Cancer Inst, (Band 88), No. 1, Seite 24-31. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0008847721 [5] Ford, A. M.; Ridge, S. A.; Cabrera, M. E.; Mahmoud, H.; Steel, C. M.; Chan, L. C. und Greaves, M. (1993): In utero rearrangements in the trithorax-related oncogene in infant leukaemias, Nature, (Band 363), No. 6427, Seite 358-60. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0008497319 [6] Gill Super, H. J.; Rothberg, P. G.; Kobayashi, H.; Freeman, A. I.; Diaz, M. O. und Rowley, J. D. (1994): Clonal, nonconstitutional rearrangements of the MLL gene in infant twins with acute lymphoblastic leukemia: in utero chromosome rearrangement of 11q23, Blood, (Band 83), No. 3, Seite 641-4. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0008298125 [7] Gale, K. B.; Ford, A. M.; Repp, R.; Borkhardt, A.; Keller, C.; Eden, O. B. und Greaves, M. F. (1997): Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots, Proc Natl Acad Sci U S A, (Band 94), No. 25, Seite 13950-4. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0009391133 [8] Greaves, M. F. (1997): Aetiology of acute leukaemia, Lancet, (Band 349), No. 9048, Seite 344-9.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9024390 [9] Ford, A.M.; Bennett, C.A.; Price, C.M.; Bruin, M.C.A.; van Wering, E.R. und Greaves, M. (1998): Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia, Proc.Natl.Acad.Sci.USA, (Band 95), Seite 4584-4588. [10] Wiemels, J. L.; Cazzaniga, G.; Daniotti, M.; Eden, O. B.; Addison, G. M.; Masera, G.; Saha, V.; Biondi, A. und Greaves, M. F. (1999): Prenatal origin of acute lymphoblastic leukaemia in children, Lancet, (Band 354), No. 9189, Seite 1499-503.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=10551495 [11] Meadows, A. T.; Kramer, S.; Hopson, R.; Lustbader, E.; Jarrett, P. und Evans, A. E. (1983): Survival in childhood acute lymphocytic leukemia: effect of protocol and place of treatment, Cancer Invest, (Band 1), No. 1, Seite 49-55. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=6582988 [12] Kersey, J. H. (1997): Fifty years of studies of the biology and therapy of childhood leukemia, Blood, (Band 90), No. 11, Seite 4243-4251. [13] Reiter, A.; Schrappe, M.; Ludwig, W. D.; Lampert, F.; Harbott, J.; Henze, G.; Niemeyer, C. M.; Gadner, H.; Muller-Weihrich, S.; Ritter, J. und et al. (1992): Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group, Blood, (Band 80), No. 10, Seite 2471-8.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=1421370 [14] Wheeler, K.; Richards, S.; Bailey, C. und Chessells, J. (1998): Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia, Br J Haematol, (Band 101), No. 1, Seite 94-103.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9576189 [15] Henze, G.; Fengler, R.; Hartmann, R.; Kornhuber, B.; Janka Schaub, G.; Niethammer, D. und Riehm, H. (1991): Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group, Blood, (Band 78), No. 5, Seite 1166-72. [16] Rubnitz, J. E.; Behm, F. G.; Wichlan, D.; Ryan, C.; Sandlund, J. T.; Ribeiro, R. C.; Rivera, G. K.; Hancock, M. L.; Relling, M. V.; Evans, W. E.; Pui, C. H. und Downing, J. R. (1999): Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup, Leukemia, (Band 13), No. 1, Seite 19-21. [17] Henze, G.; Fengler, R. und Adams, H.P. (1997): ALL-REZ BFM 96 - Studie zur Behandlung von Kindern mit Rezidiv einer akuten lymphoblastischen Leukämie. Gesellschaft für Päditrische Onkologie und Hämatologie (GPOH). [18] Gaynon, P. S.; Qu, R. P.; Chappell, R. J.; Willoughby, M. L.; Tubergen, D. G.; Steinherz, P. G. und Trigg, M. E. (1998): Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience, Cancer, (Band 82), No. 7, Seite 1387-95.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9529033 [19] Pui, C. H. (1995): Childhood leukemias, N-Engl-J-Med, (Band 332), No. 24, Seite 1618-30. [20] Loning, L.; Zimmermann, M.; Reiter, A.; Kaatsch, P.; Henze, G.; Riehm, H. und Schrappe, M. (2000): Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy, Blood, (Band 95), No. 9, Seite 2770-5.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=10779419 http://www.bloodjournal.org/cgi/content/full/95/9/2770 http://www.bloodjournal.org/cgi/content/abstract/95/9/2770 [21] Pui, C.H. und Evans, W.E. (1998): Acute lymphoblastic leukemia, N-Engl-J-Med, (Band 339), No. 9, Seite 605. [22] Reiter, A.; Schrappe, M.; Ludwig, W. D.; Hiddemann, W.; Sauter, S.; Henze, G.; Zimmermann, M.; Lampert, F.; Havers, W. und Niethammer, D. (1994): Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86, Blood, (Band 84), No. 9, Seite 3122-33. [23] Crist, W.; Shuster, J.; Look, T.; Borowitz, M.; Behm, F.; Bowman, P.; Frankel, L.; Pullen, J.; Krance, R.; Steuber, P. und et al. (1992): Current results of studies of immunophenotype-, age- and leukocyte- based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group, Leukemia, (Band 6), No. Suppl 2, Seite 162-6. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0001578922 [24] Rivera, G. K.; Pinkel, D.; Simone, J. V.; Hancock, M. L. und Crist, W. M. (1993): Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital [see comments], N Engl J Med, (Band 329), No. 18, Seite 1289-95. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0008413409 [25] Bennett, J. M.; Catovsky, D.; Daniel, M. T.; Flandrin, G.; Galton, D. A.; Gralnick, H. R. und Sultan, C. (1976): Proposals for the classification of the acute leukaemias. French- American-British (FAB) co-operative group, Br J Haematol, (Band 33), No. 4, Seite 451-8. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0000188440 [26] Lilleyman, J. S.; Hann, I. M.; Stevens, R. F.; Eden, O. B. und Richards, S. M. (1986): French American British (FAB) morphological classification of childhood lymphoblastic leukaemia and its clinical importance, J Clin Pathol, (Band 39), No. 9, Seite 998-1002. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0003463568 [27] Pui, C. H.; Behm, F. G. und Crist, W. M. (1993): Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia, Blood, (Band 82), No. 2, Seite 343-62. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0008329694 [28] Russell, N. H. (1997): Biology of acute leukaemia, Lancet, (Band 349), No. 9045, Seite 118-22. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0008996433 [29] Pui, C. H.; Raimondi, S. C.; Head, D. R.; Schell, M. J.; Rivera, G. K.; Mirro, J., Jr.; Crist, W. M. und Behm, F. G. (1991): Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse [see comments], Blood, (Band 78), No. 5, Seite 1327-37. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0001878594 [30] Rubnitz, J. E. und Look, A. T. (1998): Molecular genetics of childhood leukemias, J Pediatr Hematol Oncol, (Band 20), No. 1, Seite 1-11. [31] Rabbitts, T. H. (1994): Chromosomal translocations in human cancer, Nature, (Band 372), No. 6502, Seite 143-9. [32] Sawyers, C. L. (1997): Molecular genetics of acute leukaemia, Lancet . Jan, (Band 349), No. 9046, Seite 196-200. [33] Golub, T. R.; Slonim, D. K.; Tamayo, P.; Huard, C.; Gaasenbeek, M.; Mesirov, J. P.; Coller, H.; Loh, M. L.; Downing, J. R.; Caligiuri, M. A.; Bloomfield, C. D. und Lander, E. S. (1999): Molecular classification of cancer: class discovery and class prediction by gene expression monitoring, Science, (Band 286), No. 5439, Seite 531-7.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=10521349 [34] Camitta, B. M.; Pullen, J. und Murphy, S. (1997): Biology and treatment of acute lymphocytic leukemia in children, Semin Oncol, (Band 24), No. 1, Seite 83-91.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9045307 [35] Raimondi, S. C.; Shurtleff, S. A.; Downing, J. R.; Rubnitz, J.; Mathew, S.; Hancock, M.; Pui, C. H.; Rivera, G. K.; Grosveld, G. C. und Behm, F. G. (1997): 12p abnormalities and the TEL gene (ETV6) in childhood acute lymphoblastic leukemia, Blood, (Band 90), No. 11, Seite 4559-66. [36] Biondi, A. und Masera, G. (1998): Molecular pathogenesis of childhood acute lymphoblastic leukemia, Haematologica, (Band 83), No. 7, Seite 651-9. [37] Rubnitz, J. E.; Behm, F. G.; Pui, C. H.; Evans, W. E.; Relling, M. V.; Raimondi, S. C.; Harrison, P. L.; Sandlund, J. T.; Ribeiro, R. C.; Grosveld, G. und Downing, J. R. (1997): Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII, Leukemia, (Band 11), No. 8, Seite 1201-6. [38] Rubnitz, J. E. und Pui, C. H. (1997): Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia, Curr Opin Hematol, (Band 4), No. 4, Seite 233-41. [39] Rubnitz, J. E. und Pui, C. H. (1999): Molecular diagnostics in the treatment of leukemia [In Process Citation], Curr Opin Hematol, (Band 6), No. 4, Seite 229-35. [40] Chessells, J. M. (1998): Relapsed lymphoblastic leukaemia in children: a continuing challenge, Br J Haematol, (Band 102), No. 2, Seite 423-38. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0009695956 [41] Henze, G.; Fengler, R. und Hartmann, R. (1994): Chemotherapy for relapsed childhood acute lymphoblastic leukemia: Results of the BFM Study Group, Haematol Blood Transfus, (Band 36), Seite 374-9. [42] Raimondi, S. C. (1993): Current status of cytogenetic research in childhood acute lymphoblastic leukemia, Blood, (Band 81), No. 9, Seite 2237-51. [43] Look, A.T. (1997): Oncogenic transcription factors in the human acute leukemias, Science, (Band 278), Seite 1059. [44] Hirama, T. und Koeffler, H. P. (1995): Role of the cyclin-dependent kinase inhibitors in the development of cancer, Blood, (Band 86), No. 3, Seite 841-54. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0007620180 [45] Hebert, J.; Cayuela, J. M.; Berkeley, J. und Sigaux, F. (1994): Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias [see comments], Blood, (Band 84), No. 12, Seite 4038-44. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0007994022 [46] Latchman, D. S. (1993): Transcription factors: an overview, Int J Exp Pathol, (Band 74), No. 5, Seite 417-22. [47] Papavassiliou, A.G. (1995): Molecular medicine.Transcription factors, N-Engl-J-Med, (Band 332), Seite 45. [48] Ptashne, M. (1988): How eukaryotic transcriptional activators work, Nature, (Band 335), No. 6192, Seite 683-9. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0003050531 [49] Sigler, P. B. (1988): Transcriptional activation. Acid blobs and negative noodles [news], Nature, (Band 333), No. 6170, Seite 210-2. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0003367995 [50] Keleher, C. A.; Goutte, C. und Johnson, A. D. (1988): The yeast cell-type-specific repressor alpha 2 acts cooperatively with a non-cell-type-specific protein, Cell, (Band 53), No. 6, Seite 927-36. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0003289753 [51] Treacy, M. N.; He, X. und Rosenfeld, M. G. (1991): I-POU: a POU-domain protein that inhibits neuron-specific gene activation, Nature, (Band 350), No. 6319, Seite 577-84.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=1673230 [52] Murre C, McCaw PS , Baltimore D (1989): A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daugtherless, MyoD, and myc proteins, Cell, (Band 56), Seite 777-783. [53] Mitchell, P. J. und Tjian, R. (1989): Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins, Science, (Band 245), No. 4916, Seite 371-8. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0002667136 [54] Golub, T. R.; Barker, G. F.; Lovett, M. und Gilliland, D. G. (1994): Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation, Cell, (Band 77), No. 2, Seite 307-16. [55] Romana, S. P.; Poirel, H.; Leconiat, M.; Flexor, M. A.; Mauchauffe, M.; Jonveaux, P.; Macintyre, E. A.; Berger, R. und Bernard, O. A. (1995): High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia, Blood, (Band 86), No. 11, Seite 4263-9. [56] Romana, S. P.; Mauchauffe, M.; Le Coniat, M.; Chumakov, I.; Le Paslier, D.; Berger, R. und Bernard, O. A. (1995): The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion, Blood, (Band 85), No. 12, Seite 3662-70. [57] Wasylyk, B.; Hahn, S.L. und Giovane, A. (1993): The ETS family of transcription factors, Eur J Biochem, (Band 211), Seite 7-18. [58] Raouf, A.; Li, V.; Kola, I.; Watson, D. K. und Seth, A. (2000): The Ets1 proto-oncogene is upregulated by retinoic acid: characterization of a functional retinoic acid response element in the Ets1 promoter, Oncogene, (Band 19), No. 15, Seite 1969-74. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0010773887 [59] Donaldson, L. W.; Petersen, J. M.; Graves, B. J. und McIntosh, L. P. (1994): Secondary structure of the ETS domain places murine Ets-1 in the superfamily of winged helix-turn-helix DNA-binding proteins, Biochemistry, (Band 33), No. 46, Seite 13509-16. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0007947760 [60] Donaldson, L. W.; Petersen, J. M.; Graves, B. J. und McIntosh, L. P. (1996): Solution structure of the ETS domain from murine Ets-1: a winged helix- turn-helix DNA binding motif, Embo J, (Band 15), No. 1, Seite 125-34. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0008598195 http://www.oup.co.uk/jnls/list/embojo/hdb/Volume_15/Issue_01/150125.sgm.abs.html [61] Liang, H.; Mao, X.; Olejniczak, E. T.; Nettesheim, D. G.; Yu, L.; Meadows, R. P.; Thompson, C. B. und Fesik, S. W. (1994): Solution structure of the ets domain of Fli-1 when bound to DNA, Nat Struct Biol, (Band 1), No. 12, Seite 871-5. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0007773776 [62] Boulukos, K. E.; Pognonec, P.; Rabault, B.; Begue, A. und Ghysdael, J. (1989): Definition of an Ets1 protein domain required for nuclear localization in cells and DNA-binding activity in vitro, Mol Cell Biol, (Band 9), No. 12, Seite 5718-21. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0002555704 [63] Seth, A. und Papas, T. S. (1990): The c-ets-1 proto-oncogene has oncogenic activity and is positively autoregulated, Oncogene, (Band 5), No. 12, Seite 1761-7. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0002284095 [64] Jousset, C.; Carron, C.; Boureux, A.; Quang, C. T.; Oury, C.; Dusanter Fourt, I.; Charon, M.; Levin, J.; Bernard, O. und Ghysdael, J. (1997): A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein, Embo J, (Band 16), No. 1, Seite 69-82. [65] Carroll, M.; Tomasson, M. H.; Barker, G. F.; Golub, T. R. und Gilliland, D. G. (1996): The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways, Proc-Natl-Acad-Sci-U-S-A, (Band 93), No. 25, Seite 14845-50. [66] Golub, T. R.; McLean, T.; Stegmaier, K.; Carroll, M.; Tomasson, M. und Gilliland, D. G. (1996): The TEL gene and human leukemia, Biochim-Biophys-Acta, (Band 1288), No. 1, Seite M7-10. [67] Golub, T. R.; Goga, A.; Barker, G. F.; Afar, D. E.; McLaughlin, J.; Bohlander, S. K.; Rowley, J. D.; Witte, O. N. und Gilliland, D. G. (1996): Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia, Mol Cell Biol, (Band 16), No. 8, Seite 4107-16. [68] Golub, T. R.; Barker, G. F.; Stegmaier, K. und Gilliland, D. G. (1996): Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms, Curr Top Microbiol Immunol, (Band 211), Seite 279-88. [69] Poirel, H.; Oury, C.; Carron, C.; Duprez, E.; Laabi, Y.; Tsapis, A.; Romana, S. P.; Mauchauffe, M.; Le Coniat, M.; Berger, R.; Ghysdael, J. und Bernard, O. A. (1997): The TEL gene products: nuclear phosphoproteins with DNA binding properties, Oncogene, (Band 14), No. 3, Seite 349-57. [70] Wang, L. C.; Swat, W.; Fujiwara, Y.; Davidson, L.; Visvader, J.; Kuo, F.; Alt, F. W.; Gilliland, D. G.; Golub, T. R. und Orkin, S. H. (1998): The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow, Genes Dev, (Band 12), No. 15, Seite 2392-402. [71] Fears, S.; Gavin, M.; Zhang, D.E.; Hetherington, C.; Ben David, Y.; Rowley, J.D. und Nucifora, G. (1997): Functional characterization of ETV6 and ETV6/CBFA2 in the regulation of the MCSFR proximal promotor, Proc-Natl-Acad-Sci-U-S-A, (Band 94), Seite 1949. [72] Kwiatkowski, B. A.; Bastian, L. S.; Bauer, T. R.; Tsai, S.; Zielinska-Kwiatkowska, A. G. und Hickstein, D. D. (1998): The ets family member Tel binds to the Fli-1 oncoprotein and inhibits its transcriptional activity, J Biol Chem, (Band 273), No. 28, Seite 17525-30.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9651344 http://www.jbc.org/cgi/content/full/273/28/17525 [73] Papadopoulos, P.; Ridge, S. A.; Boucher, C. A.; Stocking, C. und Wiedemann, L. M. (1995): The novel activation of ABL by fusion to an ets-related gene, TEL, Cancer-Res, (Band 55), No. 1, Seite 34-8. [74] Buijs, A.; Sherr, S.; van Baal, S.; van Bezouw, S.; van der Plas, D.; Geurts van Kessel, A.; Riegman, P.; Lekanne Deprez, R.; Zwarthoff, E.; Hagemeijer, A. und Grosveld, G. (1995): Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11 [published erratum appears in Oncogene 1995 Aug 17;11(4):809], Oncogene, (Band 10), No. 8, Seite 1511-9. [75] O'Connor, H. E.; Butler, T. A.; Clark, R.; Swanton, S.; Harrison, C. J.; Secker Walker, L. M. und Foroni, L. (1998): Abnormalities of the ETV6 gene occur in the majority of patients with aberrations of the short arm of chromosome 12: a combined PCR and Southern blotting analysis, Leukemia, (Band 12), No. 7, Seite 1099-106. [76] Peeters, P.; Raynaud, S. D.; Cools, J.; Wlodarska, I.; Grosgeorge, J.; Philip, P.; Monpoux, F.; Van Rompaey, L.; Baens, M.; Van den Berghe, H. und Marynen, P. (1997): Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia, Blood, (Band 90), No. 7, Seite 2535-40. [77] Lacronique, V.; Boureux, A.; Valle, V. D.; Poirel, H.; Quang, C. T.; Mauchauffe, M.; Berthou, C.; Lessard, M.; Berger, R.; Ghysdael, J. und Bernard, O. A. (1997): A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia, Science, (Band 278), No. 5341, Seite 1309-12. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0009360930 [78] Baccichet, A. und Sinnett, D. (1997): Frequent deletion of chromosome 12p12.3 in children with acute lymphoblastic leukaemia, Br J Haematol, (Band 99), No. 1, Seite 107-14. [79] Peeters, P.; Wlodarska, I.; Baens, M.; Criel, A.; Selleslag, D.; Hagemeijer, A.; Van den Berghe, H. und Marynen, P. (1997): Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders, Cancer Res, (Band 57), No. 4, Seite 564-9. [80] Raynaud, S.; Cave, H.; Baens, M.; Bastard, C.; Cacheux, V.; Grosgeorge, J.; Guidal Giroux, C.; Guo, C.; Vilmer, E.; Marynen, P. und Grandchamp, B. (1996): The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia, Blood, (Band 87), No. 7, Seite 2891-9. [81] Poirel, H.; Lacronique, V.; Mauchauffe, M.; Le Coniat, M.; Raffoux, E.; Daniel, M. T.; Erickson, P.; Drabkin, H.; MacLeod, R. A.; Drexler, H. G.; Ghysdael, J.; Berger, R. und Bernard, O. A. (1998): Analysis of TEL proteins in human leukemias, Oncogene, (Band 16), No. 22, Seite 2895-903. [82] Kobayashi, H.; Satake, N.; Maseki, N.; Sakashita, A. und Kaneko, Y. (1996): The der(21)t(12;21) chromosome is always formed in a 12;21 translocation associated with childhood acute lymphoblastic leukaemia, Br J Haematol, (Band 94), No. 1, Seite 105-11. [83] Miyoshi, H.; Shimizu, K.; Kozu, T.; Maseki, N.; Kaneko, Y. und Ohki, M. (1991): The t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1, Proc-Natl-Acad-Sci-U-S-A, (Band 88), No. 23, Seite 10431-4. [84] Miyoshi, H.; Ohira, M.; Shimizu, K.; Mitani, K.; Hirai, H.; Imai, T.; Yokoyama, K.; Soeda, E. und Ohki, M. (1995): Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia, Nucleic-Acids-Res, (Band 23), No. 14, Seite 2762-9. [85] Crute, B. E.; Lewis, A. F.; Wu, Z. N.; Bushweller, J. H. und Speck, N. A. (1996): Biochemical and biophysical properties of the core binding factor alpha 2 (aml1) dna binding domain, Journal Of Biological Chemistry. Oct, (Band 271), No. 42, Seite 26251-26260. [86] Daga, A.; Karlovich, C. A.; Dumstrei, K. und Banerjee, U. (1996): Patterning of cells in the Drosophila eye by Lozenge, which shares homologous domains with AML1, Genes Dev, (Band 10), No. 10, Seite 1194-205. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0008675007 [87] Tanaka, T.; Kurokawa, M.; Ueki, K.; Tanaka, K.; Imai, Y.; Mitani, K.; Okazaki, K.; Sagata, N.; Yazaki, Y.; Shibata, Y.; Kadowaki, T. und Hirai, H. (1996): The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability, Mol-Cell-Biol, (Band 16), No. 7, Seite 3967-79. [88] Zeng, C.; van Wijnen, A. J.; Stein, J. L.; Meyers, S.; Sun, W.; Shopland, L.; Lawrence, J. B.; Penman, S.; Lian, J. B.; Stein, G. S. und Hiebert, S. W. (1997): Identification of a nuclear matrix targeting signal in the leukemia and bone-related AML/CBF-alpha transcription factors, Proc Natl Acad Sci U S A, (Band 94), No. 13, Seite 6746-51. [89] Chen, Q.; Cheng, J. T.; Tasi, L. H.; Schneider, N.; Buchanan, G.; Carroll, A.; Crist, W.; Ozanne, B.; Siciliano, M. J. und Baer, R. (1990): The tal gene undergoes chromosome translocation in T cell leukemia and potentially encodes a helix-loop-helix protein, Embo J, (Band 9), No. 2, Seite 415-24. [90] Tanaka, T.; Tanaka, K.; Ogawa, S.; Kurokawa, M.; Mitani, K.; Yazaki, Y.; Shibata, Y. und Hirai, H. (1997): An acute myeloid leukemia gene, AML1, regulates transcriptional activation and hemopoietic myeloid cell differentiation antagonistically by two alternative spliced forms, Leukemia, (Band 3), Seite 299-302. [91] Lu, Q.; Knoepfler, P. S.; Scheele, J.; Wright, D. D. und Kamps, M. P. (1995): Both Pbx1 and E2A-Pbx1 bind the DNA motif ATCAATCAA cooperatively with the products of multiple murine Hox genes, some of which are themselves oncogenes, Mol Cell Biol, (Band 15), No. 7, Seite 3786-95. [92] Chiba, N.; Watanabe, T.; Nomura, S.; Tanaka, Y.; Minowa, M.; Niki, M.; Kanamaru, R. und Satake, M. (1997): Differentiation dependent expression and distinct subcellular localization of the protooncogene product, PEBP2beta/CBFbeta, in muscle development, Oncogene, (Band 14), No. 21, Seite 2543-52. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0009191054 [93] Kitabayashi, I.; Yokoyama, A.; Shimizu, K. und Ohki, M. (1998): Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation, Embo J, (Band 17), No. 11, Seite 2994-3004. [94] Levanon, D.; Negreanu, V.; Bernstein, Y.; Bar Am, I.; Avivi, L. und Groner, Y. (1994): AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization, Genomics, (Band 23), No. 2, Seite 425-32. [95] Takahashi, A.; Satake, M.; Yamaguchi-Iwai, Y.; Bae, S. C.; Lu, J.; Maruyama, M.; Zhang, Y. W.; Oka, H.; Arai, N.; Arai, K. und et al. (1995): Positive and negative regulation of granulocyte-macrophage colony- stimulating factor promoter activity by AML1-related transcription factor, PEBP2, Blood, (Band 86), No. 2, Seite 607-16. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0007605990 [96] Ogawa, E.; Maruyama, M.; Kagoshima, H.; Inuzuka, M.; Lu, J.; Satake, M.; Shigesada, K. und Ito, Y. (1993): PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene, Proc-Natl-Acad-Sci-U-S-A, (Band 90), No. 14, Seite 6859-63. [97] Wang, Q.; Stacy, T.; Miller, J. D.; Lewis, A. F.; Gu, T. L.; Huang, X. M.; Bushweller, J. H.; Bories, J. C.; Alt, F. W.; Ryan, G.; Liu, P. P.; Wynshawboris, A.; Binder, M.; Marinpadilla, M.; Sharpe, A. H. und Speck, N. A. (1996): The cbf beta subunit is essential for cbf alpha 2 (aml1) function in vivo, Cell . Nov, (Band 87), No. 4, Seite 697-708. [98] Meyers, S.; Lenny, N. und Hiebert, S. W. (1995): The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation, Mol-Cell-Biol, (Band 15), No. 4, Seite 1974-82. [99] Sun, W.; O'Connell, M. und Speck, N. A. (1993): Characterization of a protein that binds multiple sequences in mammalian type C retrovirus enhancers, J Virol, (Band 67), No. 4, Seite 1976-86.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8445719 [100] Carey, M. (1998): The enhanceosome and transcriptional synergy, Cell, (Band 92), No. 1, Seite 5-8.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9489694 [101] Meyers, S.; Downing, J. R. und Hiebert, S. W. (1993): Identification of AML-1 and the (8;21) translocation protein (AML- 1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions, Mol Cell Biol, (Band 13), No. 10, Seite 6336-45.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8413232 [102] Daga, A.; Tighe, J. E. und Calabi, F. (1992): Leukaemia/Drosophila homology, Nature, (Band 356), No. 6369, Seite 484.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=1560822 [103] Corsetti, M.T. und Calabi, F. (1997): Lineage and stage specific expression of runt box polypeptides in primitive and definitive hematopoiesis, Blood, (Band 89), Seite 321. [104] Okuda, T.; van Deursen, J.; Hiebert, S. W.; Grosveld, G. und Downing, J. R. (1996): AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis, Cell, (Band 84), No. 2, Seite 321-30. [105] Sasaki, K.; Yagi, H.; Bronson, R. T.; Tominaga, K.; Matsunashi, T.; Deguchi, K.; Tani, Y.; Kishimoto, T. und Komori, T. (1996): Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta, Proc-Natl-Acad-Sci-U-S-A, (Band 93), No. 22, Seite 12359-63. [106] Tanaka, T.; Tanaka, K.; Ogowa, S.; Kurokawa, M.; Mitani, K.; Nishida, J.; Shibata, Y.; Yazaki, Y. und Hirai, H. (1995): An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transkriptional activation antagonistically by two alternative spliced forms, EMBO-J, (Band 14), Seite 341. [107] Chen, J. und Ruley, H. E. (1998): An enhancer element in the EphA2 (Eck) gene sufficient for rhombomere-specific expression is activated by HOXA1 and HOXB1 homeobox proteins, J Biol Chem, (Band 273), No. 38, Seite 24670-5. [108] Liebermann, D. A. und Hoffman, B. (1998): MyD genes in negative growth control, Oncogene, (Band 17), No. 25, Seite 3319-29.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9916994 [109] Okuda, T.; Cai, Z.; Yang, S.; Lenny, N.; Lyu, C. J.; van Deursen, J. M.; Harada, H. und Downing, J. R. (1998): Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors, Blood, (Band 91), No. 9, Seite 3134-43. [110] Kanno, T.; Kanno, Y.; Chen, L. F.; Ogawa, E.; Kim, W. Y. und Ito, Y. (1998): Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor alpha subunit revealed in the presence of the beta subunit, Mol Cell Biol, (Band 18), No. 5, Seite 2444-54.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9566865 [111] Adya, N.; Stacy, T.; Speck, N. A. und Liu, P. P. (1998): The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates, Mol Cell Biol, (Band 18), No. 12, Seite 7432-43.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9819429 http://mcb.asm.org/cgi/content/full/18/12/7432 [112] Liu, P.; Tarle, S. A.; Hajra, A.; Claxton, D. F.; Marlton, P.; Freedman, M.; Siciliano, M. J. und Collins, F. S. (1993): Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia, Science, (Band 261), No. 5124, Seite 1041-4. [113] Shurtleff, S. A.; Buijs, A.; Behm, F. G.; Rubnitz, J. E.; Raimondi, S. C.; Hancock, M. L.; Chan, G. C.; Pui, C. H.; Grosveld, G. und Downing, J. R. (1995): TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis, Leukemia, (Band 9), No. 12, Seite 1985-9. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0008609706 [114] Nakao, M.; Yokota, S.; Horiike, S.; Taniwaki, M.; Kashima, K.; Sonoda, Y.; Koizumi, S.; Takaue, Y.; Matsushita, T.; Fujimoto, T. und Misawa, S. (1996): Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia, Leukemia, (Band 10), No. 9, Seite 1463-70. [115] McLean, T. W.; Ringold, S.; Neuberg, D.; Stegmaier, K.; Tantravahi, R.; Ritz, J.; Koeffler, H. P.; Takeuchi, S.; Janssen, J. W.; Seriu, T.; Bartram, C. R.; Sallan, S. E.; Gilliland, D. G. und Golub, T. R. (1996): TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia, Blood, (Band 88), No. 11, Seite 4252-8. [116] Rubnitz, J. E.; Downing, J. R.; Pui, C. H.; Shurtleff, S. A.; Raimondi, S. C.; Evans, W. E.; Head, D. R.; Crist, W. M.; Rivera, G. K.; Hancock, M. L.; Boyett, J. M.; Buijs, A.; Grosveld, G. und Behm, F. G. (1997): TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance, J Clin Oncol, (Band 15), No. 3, Seite 1150-7. [117] Rubnitz, J. E.; Shuster, J. J.; Land, V. J.; Link, M. P.; Pullen, D. J.; Camitta, B. M.; Pui, C. H.; Downing, J. R. und Behm, F. G. (1997): Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study, Blood, (Band 89), No. 4, Seite 1143-6. [118] Raynaud, S.; Mauvieux, L.; Cayuela, J. M.; Bastard, C.; Bilhou Nabera, C.; Debuire, B.; Bories, D.; Boucheix, C.; Charrin, C.; Fiere, D. und Gabert, J. (1996): TEL/AML1 fusion gene is a rare event in adult acute lymphoblastic leukemia, Leukemia, (Band 10), No. 9, Seite 1529-30. [119] Agular, R. C. T.; Sohal, J.; Vanrhee, F.; Carapeti, M.; Franklin, I. M.; Goldstone, A. H.; Goldman, J. M. und Cross, N. C. P. (1996): Tel aml1 fusion in acute lymphoblastic leukaemia of adults, British Journal Of Haematology. Dec, (Band 95), No. 4, Seite 673-677. [120] Golub, T. R.; Barker, G. F.; Bohlander, S. K.; Hiebert, S. W.; Ward, D. C.; Bray Ward, P.; Morgan, E.; Raimondi, S. C.; Rowley, J. D. und Gilliland, D. G. (1995): Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia, Proc-Natl-Acad-Sci-U-S-A, (Band 92), No. 11, Seite 4917-21. [121] Bernard, O. A.; Romana, S. P.; Poirel, H. und Berger, R. (1996): Molecular cytogenetics of t(12;21) (p13;q22), Leuk Lymphoma, (Band 23), No. 5-6, Seite 459-65. [122] Bartolo, C. (1999): TEL-AML1 alternative transcripts in pediatric ALL: Significance for minimal residual disease testing., The American Society of Hematology. [123] Hiebert, S. W.; Sun, W.; Davis, J. N.; Golub, T.; Shurtleff, S.; Buijs, A.; Downing, J. R.; Grosveld, G.; Roussell, M. F.; Gilliland, D. G.; Lenny, N. und Meyers, S. (1996): The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription, Mol Cell Biol, (Band 16), No. 4, Seite 1349-55. [124] Bemardin, F. (1999): TEL-AML1 binds endogenous TEL an slows the proliferation of Ba/F3 pro-B cells., The American Society of Hematology. [125] Meyers, S.; Lenny, N.; Sun, W. und Hiebert, S. W. (1996): AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia, Oncogene, (Band 13), No. 2, Seite 303-12. [126] Seeger, K.; Buchwald, D.; Peter, A.; Taube, T.; von Stackelberg, A.; Schmitt, G. und Henze, G. (1999): TEL-AML1 fusion in relapsed childhood acute lymphoblastic leukemia [letter; comment], Blood, (Band 94), No. 1, Seite 374-6. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0010428549 [127] Stegmaier, K.; Takeuchi, S.; Golub, T. R.; Bohlander, S. K.; Bartram, C. R. und Koeffler, H. P. (1996): Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia, Cancer-Res, (Band 56), No. 6, Seite 1413-7. [128] Romana, S. P.; Le Coniat, M.; Poirel, H.; Marynen, P.; Bernard, O. und Berger, R. (1996): Deletion of the short arm of chromosome 12 is a secondary event in acute lymphoblastic leukemia with t(12;21), Leukemia, (Band 10), No. 1, Seite 167-70. [129] Yonemura, Y.; Ku, H.; Hirayama, F.; Souza, L. M. und Ogawa, M. (1996): Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells, Proc Natl Acad Sci U S A, (Band 93), No. 9, Seite 4040-4.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=8633013 [130] Uchida, H.; Zhang, J. und Nimer, S. D. (1997): AML1A and AML1B can transactivate the human IL-3 promoter, J Immunol, (Band 158), No. 5, Seite 2251-8. [131] Borkhardt, A.; Cazzaniga, G.; Viehmann, S.; Valsecchi, M.G.; Ludwig, W-D.; Burci, L.; Mangioni, s.; Schrappe, M.; Riehm, M.; Lampert, M.; Basso, G.; Masera, G.; Harbott, G. und Biondi, A. (1997): Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enroled in German and Italian multicenter therapy trials, Blood, (Band 90), Seite 571. [132] Takahashi, Y.; Horibe, K.; Kiyoi, H.; Miyashita, Y.; Fukuda, M.; Mori, H.; Nozaki, C.; Hasegawa, S.; Kawabe, T.; Kato, K.; Kojima, S.; Matuyama, T. und Naoe, T. (1998): Prognostic significance of TEL/AML1 fusion transcript in childhood B- precursor acute lymphoblastic leukemia, J Pediatr Hematol Oncol, (Band 20), No. 3, Seite 190-5. [133] Pui, C. H.; Rubnitz, J. E.; Hancock, M. L.; Downing, J. R.; Raimondi, S. C.; Rivera, G. K.; Sandlund, J. T.; Ribeiro, R. C.; Head, D. R.; Relling, M. V.; Evans, W. E. und Behm, F. G. (1998): Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia, J Clin Oncol, (Band 16), No. 12, Seite 3768-73. [134] Baruchel, A.; Cayuela, J. M.; Ballerini, P.; Landman-Parker, J.; Cezard, V.; Firat, H.; Haddad, E.; Auclerc, M. F.; Valensi, F.; Cayre, Y. E.; Macintyre, E. A. und Sigaux, F. (1997): The majority of myeloid-antigen-positive (My+) childhood B-cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts, Br J Haematol, (Band 99), No. 1, Seite 101-6. [135] Smith, M.; Arthur, D.; Camitta, B.; Carroll, A. J.; Crist, W.; Gaynon, P.; Gelber, R.; Heerema, N.; Korn, E. L.; Link, M.; Murphy, S.; Pui, C. H.; Pullen, J.; Reamon, G.; Sallan, S. E.; Sather, H.; Shuster, J.; Simon, R.; Trigg, M.; Tubergen, D.; Uckun, F. und Ungerleider, R. (1996): Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia [see comments], J-Clin-Oncol, (Band 14), No. 1, Seite 18-24. [136] Seeger, K.; Adams, H. P.; Buchwald, D.; Beyermann, B.; Kremens, B.; Niemeyer, C.; Ritter, J.; Schwabe, D.; Harms, D.; Schrappe, M. und Henze, G. (1998): TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group, Blood, (Band 91), No. 5, Seite 1716-22. [137] Southern, E. M. (1975): Detection of specific sequences among DNA fragments separated by gel electrophoresis, J Mol Biol, (Band 98), No. 3, Seite 503-17. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0001195397 [138] Hodges, K. A.; Kosciol, C. M.; Rezuke, W. N.; Abernathy, E. C.; Pastuszak, W. T. und Tsongalis, G. J. (1996): Chemiluminescent detection of gene rearrangements in hematologic malignancy, Ann Clin Lab Sci, (Band 26), No. 2, Seite 114-8. [139] Uchida, H.; Zhang, J. und Nimer, S. D. (1997): Aml1a and aml1b can transactivate the human il 3 promoter, Journal Of Immunology. Mar, (Band 158), No. 5, Seite 2251-2258. [140] Liang, D. C.; Chou, T. B.; Chen, J. S.; Shurtleff, S. A.; Rubnitz, J. E.; Downing, J. R.; Pui, C. H. und Shih, L. Y. (1996): High incidence of TEL/AML1 fusion resulting from a cryptic t(12;21) in childhood B-lineage acute lymphoblastic leukemia in Taiwan, Leukemia, (Band 10), No. 6, Seite 991-3. [141] Fears, S.; Vignon, C.; Bohlander, S. K.; Smith, S.; Rowley, J. D. und Nucifora, G. (1996): Correlation between the ETV6/CBFA2 (TEL/AML1) fusion gene and karyotypic abnormalities in children with B-cell precursor acute lymphoblastic leukemia, Genes Chromosomes Cancer, (Band 17), No. 2, Seite 127-35. [142] Ayigad, S.; Kuperstein, G.; Zilberstein, J.; Liberzon, E.; Stark, B.; Gelernter, I.; Kodman, Y.; Luria, D.; Ash, S.; Stein, J.; Goshen, Y.; Yaniv, I.; Cohen, I. J. und Zaizov, R. (1999): TEL-AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia [letter], Leukemia, (Band 13), No. 3, Seite 481-3. [143] Rubnitz, J. E.; Pui, C. H. und Downing, J. R. (1999): The role of TEL fusion genes in pediatric leukemias, Leukemia, (Band 13), No. 1, Seite 6-13. [144] Cayuela, J. M.; Baruchel, A.; Orange, C.; Madani, A.; Auclerc, M. F.; Daniel, M. T.; Schaison, G. und Sigaux, F. (1996): TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia, Blood, (Band 88), No. 1, Seite 302-8. [145] Satake, N.; Kobayashi, H.; Tsunematsu, Y.; Kawasaki, H. und Horikoshi, Y. (1997): Minimal residual disease with TEL-AML1 fusion transkript in childhood acute lymphoblastic leukemia with t(12;21), British J. Haematol., (Band 97), Seite 607. [146] Zuna, J.; Hrusak, O.; Kalinova, M.; Muzikova, K.; Stary, J. und Trka, J. (1999): TEL/AML1 positivity in childhood ALL: average or better prognosis? Czech Paediatric Haematology Working Group, Leukemia, (Band 13), No. 1, Seite 22-4. [147] Loh, M.L. (1999): Response Letter, Blood, (Band 94), No. 1, Seite 375-376. [148] Seeger, K.; Buchwald, D.; Taube, T.; Peter, A.; von Stackelberg, A.; Schmitt, G.; Kochling, J. und Henze, G. (1999): TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood. Berlin-Frankfurt-Munster Study Group [letter] [see comments], Leukemia, (Band 13), No. 9, Seite 1469-70. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0010483004 [149] Rubnitz, J. E.; Downing, J. R. und Pui, C. H. (1999): Significance of the TEL-AML fusion gene in childhood AML, Leukemia, (Band 13), No. 9, Seite 1470-1.. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=10483005 [150] Loh, M. L.; Silverman, L. B.; Young, M. L.; Neuberg, D.; Golub, T. R.; Sallan, S. E. und Gilliland, D. G. (1998): Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia, Blood, (Band 92), No. 12, Seite 4792-7. [151] Harbott, J.; Viehmann, S.; Borkhardt, A.; Henze, G. und Lampert, F. (1997): Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse, Blood, (Band 90), No. 12, Seite 4933-7. [152] Nygaard, R.; Moe, P. J.; Brincker, H.; Clausen, N.; Nyman, R.; Perkkio, M.; Eilertsen, M. E.; Johansen, O. J.; Vare, M.; Brinch, L. und et al. (1989): Late relapses after treatment for acute lymphoblastic leukemia in childhood: a population-based study from the Nordic countries, Med Pediatr Oncol, (Band 17), No. 1, Seite 45-7. http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0002913474 [153] Berger, R.; Leconiat, M.; Romana, S. P. und Jonveaux, P. (1996): Secondary acute myeloblastic leukemia with t(16 21)(q24 q22) involving the aml1 gene, Hematology And Cell Therapy. Apr, (Band 38), No. 2, Seite 183-186. [154] Zent, C.; Kim, N.; Hiebert, S.; Zhang, D. E.; Tenen, D. G.; Rowley, J. D. und Nucifora, G. (1996): Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties, Curr Top Microbiol Immunol, (Band 211), Seite 243-52. [155] Filatov, L. V.; Saito, M.; Behm, F. G.; Rivera, G. K. und Raimondi, S. C. (1996): A subtle deletion of 12p by routine cytogenetics is found to be a translocation to 21q by fluorescence in situ hybridization: t(12;21)(p13;q22), Cancer-Genet-Cytogenet, (Band 89), No. 2, Seite 136-40.